been shown to exert protective effects against ventricular remodeling in an animal model of heart failure. 10 In human limbal epithelial cells, doxycycline is known to inhibit the p-ERK/ERK pathway. 11 In murine T-lymphocytes, next-generation sequencing has shown that doxycycline can modify microRNA expression profiles. 12 Using a chronic intermittent hypoxia model in rats, we tested the hypothesis that doxycycline can prevent atrial remodeling, potentially through modulation of the miR-21/ERK signaling pathway.
| MATERIAL S AND ME THODS

| Experimental animals and protocol
This study was approved by the Experimental Animal Administration
Committee of Tianjin Medical University and Tianjin Municipal
Commission for Experimental Animal Control. ARRIVE guidelines were followed in our experiments. Thirty Sprague Dawley male rats (200-250 g and 8 weeks old) were randomized into three groups:
(1) control group, (2) chronic intermittent hypoxia (CIH) group, and Rats were placed inside a Plexiglas chamber that was connected to an automated system of valves to control ambient levels of O 2 .
Rats were acclimated to the chambers with normoxic room air (21% O 2 -79%N 2 ) for at least 3 days. They were then subjected to our CIH protocol for 28 days. Briefly, this consisted of cycling the air inside chamber between 21% and 8% O 2 for five hours each day. This was achieved by alternately flushing with 100% nitrogen to gradually reduce ambient O 2 to 8%. Chambers were then flushed with oxygen to increase O 2 back to 21%. Chamber remained at a nadir of 8% O 2 for 90s of each 5-minutes cycle of intermittent hypoxia. Control rats were also placed in the setup during the same period of time, but no obstructions were applied. Rats in all groups were progressively adapted to the experimental setting by increasing the time within the CIH device at a rate of 1 hour each day, up to 5 hours at the end of the first week.
During the remaining 19 hours of each day, all rats were housed in a controlled environment and had free access to rodent chow and tap water, breathing normoxic room air.
| Echocardiography
Transthoracic echocardiography was performed after the 4 weeks CIH using the Philips 7500 machine. The following parameters were determined: left atrial diameter (LAD), interventricular septal thickness (IVS), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), right ventricular diameter (RVD), mean pulmonary artery pressure (mPAP), and left ventricular ejection fraction (LVEF).
| Sample collection
After anesthetization with intraperitoneal urethane 10% (1 g/kg), median sternotomy was immediately performed. Blood samples were collected in EDTA tubes and centrifuged for 15 minutes at 2664 g. Plasma was collected and frozen at −80°C. Hearts were quickly removed and weighted, and atrial tissue samples were obtained from atrium. Samples were snap-frozen in liquid nitrogen for molecular biology analysis. For histological studies, transversal sections from the midventricular and basal (including both atria) regions of the heart were obtained, fixed in formalin 4% for 48 hours and then embedded in paraffin.
| Masson's trichrome staining
Atrial tissue specimens were fixed in 4% paraformaldehyde, paraffinembedded, and sliced into 5-μm-thick sections. The paraffin sections were quickly dissected and immersed in 10% neutral-buffered formalin and stained with Masson's trichrome (Accustain HT15; SigmaAldrich, St. Louis, MO, USA) for 24 hours to detect the fibrotic areas.
Fibrosis tissue was quantified with ImageJ 1.45s software. The collagen volume fraction was calculated as the mean ratio of the connective tissue to the total tissue area from all of the measurements from the section, omitting fibrosis from the perivascular, epicardial, and endocardial areas.
| Real-time PCR
Total RNA was isolated with TRIzol reagent (Invitrogen, Chicago, USA) and the RNA sample was quantified using fluorescence spec- , and GAPDH was used as an internal control. The primers used are shown in Table 1 . 
| Western blot analysis
| Statistical analysis
Data were presented as mean ± SEM. Comparisons were made using one-way ANOVA followed by Bonferroni correction. Statistical analysis was performed with SPSS v16.0. A P-value <.05 was considered statistically significant.
| RE SULTS
| Effects of CIH on body and heart weights and parameters assessed by echocardiography
No significant difference in body weight or heart weight was observed between the control, chronic intermittent hypoxia (CIH), and CIH with doxycycline treatment (CIH-D) groups (296.20 ± 23.65 vs.
318.20 ± 57.02 vs. 307.30 ± 48.72 g, respectively; n = 10; P > .05). The findings of transthoracic echocardiography are detailed in Table 2 .
Our experiments showed normal dimensions of left atrial diameter 
| Atrial fibrosis induced by CIH can be attenuated by doxycycline
Atrial fibrosis was evaluated histologically with representative photomicrographs of Masson-stained atrial sections from rats in the * and ** indicate significant difference when compared to the control group at P < .05 and .01, respectively. # indicates comparison with the chronic intermittent hypoxia (CIH) group at P < .05. NS indicates no significant difference (P > .05) F I G U R E 3 Protein levels of atrial fibrosis-related proteins determined by Western blot for Sprouty1 (Spry1, A), Matrix Metalloproteinase-2 (MMP-2, B), Metalloproteinase-9 (MMP-9, C), extracellular signal-regulated kinases (ERK1/2, D), and phosphorylated extracellular signal-regulated kinases 1/2 (p-ERK1/2, E) in control, CIH, and CIH-D groups (n = 5). * and ** indicate significant difference when compared to the control group at P < .05 and.01, respectively. # indicates comparison with the chronic intermittent hypoxia (CIH) group at P < .05. NS indicates no significant difference (P > .05) control, CIH, and CIH-D groups shown in Figure 1A -C, respectively.
CIH induced a significant 63% higher atrial interstitial collagen deposition as compared to the control group (P < .05, Figure 1D ). The collagen deposition was diffuse and homogenous, with no patchy fibrotic infiltrates in any of the analyzed samples.
| Increased fibrosis associated with miR-21 upregulation and ERK1/2 phosphorylation can be prevented by doxycycline
The mRNA levels of the different signaling molecules are shown in Figure 2 . The results showed that miR-21 was upregulated in the CIH group compared to the control group (P < .01, Figure 2A ), and this upregulation was significantly attenuated by doxycycline (P < .05 when compared to control and CIH groups). Spry1, a downstream target of miR-21, was downregulated in the CIH group compared to the control group, which was attenuated by doxycycline ( Figure 2B ).
MMP-2 and MMP-9 mRNA expression in atria were analyzed, demonstrating opposing changes. The expression of MMP-2 mRNA was reduced ( Figure 2C ), whereas that of MMP-9 was increased ( Figure 2D ), with both changes being reversed by doxycycline.
Subsequent Western blot experiments confirmed the above mRNA studies (Figure 3) . Thus, Spry1 ( Figure 3A ) and MMP-2 ( Figure 3B ) protein levels were significantly lower, whereas MMP-9 protein levels were significantly higher ( Figure 3C ) in the CIH group when compared to the control group. Moreover, further experiments demonstrated protein levels of both ERK1/2 and phosphorylated ERK1/2 were significantly increased in the CIH group when compared to control group ( Figures 3D and E) . All of these changes were attenuated by doxycycline.
| D ISCUSS I ON
The main findings of this study are that (1) CIH induced atrial fibrosis and (2) doxycycline attenuated atrial fibrosis, inhibited the miR-21/ ERK signaling pathway and modulated expression of MMPs.
Atrial structural remodeling, particularly atrial fibrosis, is a significant contributor to the arrhythmic substrate in AF, 2 and its presence has been associated with poor treatment outcomes. 13 Recent studies reported that rats which are chronically exposed to recurrent episodes of apnea developed atrial fibrosis. 14, 15 In our study, we subjected rats to 4 weeks of CIH, that significantly increased interstitial collagen deposition, indicating the presence of atrial fibrosis.
Doxycycline, a tetracycline antibiotic, is a nonspecific MMP inhibitor. 9 Previous experiments have demonstrated that its application led to reductions in the levels of inflammatory biomarkers in patients with abdominal aortic aneurysms, reducing the risk of acute coronary syndromes and pulmonary fibrosis. [16] [17] [18] [19] Riba et al 10 reported
that doxycycline was able to reduce excessive fibrosis in a postmyocardial infarction heart failure animal model.
Our experiments described in this study provide the novel data that doxycycline remarkably attenuates atrial fibrosis induced by CIH. We then went on to explore the molecular mechanisms by which this was achieved. Recent experiments have identified the important role of mitogen-activated protein kinase (MAPK)/transforming growth factor β1 pathway in atrial fibrosis. 20 teolytic enzymes that regulate ECM turnover. 25 Of these, MMP-9 is a known pro-inflammatory and profibrotic marker, and elevated levels of MMP-9 are related to the initiation and perpetuation of AF in humans. 26, 27 In our study, atrial fibrosis induced by CIH was associated with increased expression of MMP-9, which was attenuated by doxycycline. These findings are consistent with previous studies demonstrating that either gene deletion or pharmacological inhibition of MMP-9 activity attenuates atrial remodeling, thereby decreasing the vulnerability to AF. 28, 29 By contrast, MMP-2 is a marker of the anti-inflammatory and antifibrotic activity. In chronic recurrent apneas-induced model, MMP-2 expression was significantly decreased in both atria, but treatment with mesenchymal stem cells attenuated atrial fibrosis and normalized MMP-2 expression, suggesting that MMP-2 may play a key role in chronic recurrent apnea-induced atrial fibrosis. 15 We also found downregulation of MMP-2 following CIH but MMP-2 levels were restored following doxycycline treatment. These results are consistent with a previous study which showed that doxycycline regulates MMP-2 activity and expression. 30 Together our work demonstrates that a MMP-2/MMP-9 balance may underlie pro-/antifibrotic activities and that this can be manipulated by doxycycline. 
| LI M ITATI O N S
| CON CLUS IONS
Our study demonstrated that CIH treatment induced significant atrial fibrosis in our rat model, which was attenuated by doxycycline. These changes can be explained by alterations in the MMP and miR-21/ERK signaling pathways. And our study supports further research in the role of doxycycline in patients with atrial fibrosis or AF.
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